| [1] |
Chinese Society of Infectious Diseases, Chinese Society of Hepatology. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. |
| [2] |
Adverse Drug Reaction Research Center of Chinese Society of Dermatology. Expert consensus on the diagnosis and treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis[J]. Chin J Dermatol, 2021, 54(5): 376-381. DOI: 10.35541/cjd.20201177. 中华医学会皮肤性病学分会药物不良反应研究中心. Stevens-Johnson综合征/中毒性表皮坏死松解症诊疗专家共识[J]. 中华皮肤科杂志, 2021, 54(5): 376-381. DOI: 10.35541/cjd.20201177. |
| [3] |
|
| [4] |
TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800. |
| [5] |
European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021. |
| [6] |
MAZZUCCO CE, HAMATAKE RK, COLONNO RJ, et al. Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition[J]. Antimicrob Agents Chemother, 2008, 52(2): 598-605. DOI: 10.1128/AAC.01122-07. |
| [7] |
MANNS MP, AKARCA US, CHANG TT, et al. Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901[J]. Expert Opin Drug Saf, 2012, 11(3): 361-368. DOI: 10.1517/14740338.2012.653340. |
| [8] |
SUGIURA K, SUGIURA M, TAKASHI T, et al. Immediate allergy, drug-induced eruption, by entecavir[J]. J Eur Acad Dermatol Venereol, 2009, 23(4): 487-489. DOI: 10.1111/j.1468-3083.2008.02932.x. |
| [9] |
YAMADA S, SAWADA Y, NAKAMURA M. Maculopapular-type drug eruption caused by entecavir[J]. Eur J Dermatol, 2011, 21(4): 635-636. DOI: 10.1684/ejd.2011.1411. |
| [10] |
YOON J, PARK D, KIM C. A granulomatous drug eruption induced by entecavir[J]. Ann Dermatol, 2013, 25(4): 493-495. DOI: 10.5021/ad.2013.25.4.493. |
| [11] |
TAURA M, ASAI J, CHO Z, et al. Drug eruption due to entecavir: A case report and mini-review[J]. Allergol Int, 2016, 65(3): 334-335. DOI: 10.1016/j.alit.2015.12.008. |
| [12] |
KIM JT, JEONG HW, CHOI KH, et al. Delayed hypersensitivity reaction resulting in maculopapular-type eruption due to entecavir in the treatment of chronic hepatitis B[J]. World J Gastroenterol, 2014, 20(42): 15931-15936. DOI: 10.3748/wjg.v20.i42.15931. |
| [13] |
TEMIZ SA, ÖZER I ·, ATASEVEN A, et al. A case of entecavir-associated bullous fixed drug eruption and a review of literature[J]. Turk J Gastroenterol, 2019, 30(3): 299-302. DOI: 10.5152/tjg.2018.17887. |
| [14] |
CHEONG XK, WONG Z, NOR NM, et al. "Black box warning" rash with entecavir-case report[J]. BMC Gastroenterol, 2020, 20(1): 305. DOI: 10.1186/s12876-020-01452-3. |
| [15] |
HSU DY, BRIEVA J, SILVERBERG NB, et al. Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults[J]. J Invest Dermatol, 2016, 136(7): 1387-1397. DOI: 10.1016/j.jid.2016.03.023. |
| [16] |
LERCH M, MAINETTI C, TERZIROLI BERETTA-PICCOLI B, et al. Current Perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis[J]. Clin Rev Allergy Immunol, 2018, 54(1): 147-176. DOI: 10.1007/s12016-017-8654-z. |
| [17] |
KANG DY, YUN J, LEE SY, et al. A nationwide study of severe cutaneous adverse reactions based on the multicenter registry in Korea[J]. J Allergy Clin Immunol Pract, 2021, 9(2): 929-936. e7. DOI: 10.1016/j.jaip.2020.09.011. |
| [18] |
YE YJ, ZHU YP, XU AE. Clinical analysis of 73 patients with Stevens Johnson syndrome or toxic epidermal necrolysis[J]. Chin J Gen Pract, 2017, 15(10): 1691-1693, 1794. DOI: 10.16766/j.cnki.issn.1674-4152.2017.10.016. |
DownLoad: